Naha et al  
Journal of Drug Delivery & Therapeutics; 2014, 4(5), 190-192

Available online on 15.09.2014 at http://jddtonline.info

RESEARCH ARTICLE

PREPARATION AND EVALUATION OF POLYMERIC NANOPARTICLES OF GLIBENCLAMIDE

Naha Anup*, Kiran Sai, Rai Ikya, Vora Bhavisha, Reddy D Apoorva, P Kartika

Department of Pharmaceutics, Manipal College of Pharmaceutical Sciences, Manipal University, Manipal- 576104, Karnataka, India.

*Corresponding AuthorE-mail: anupnaha@gmail.com

ABSTRACT

Simple, reliable and reproducible method was used for the preparation of polymeric nanoparticles of Glibenclamide. The formulation was prepared by solvent evaporation method using magnetic stirrer with overnight stirring and the same was then evaluated for its particle size, drug content and in vitro dissolution studies. The above mentioned method showed similar particle size and exhibited an improvement in the drug entrapment efficiency. The ultraviolet spectrophotometric method was used to analyze Glibenclamide at 300 nm in different buffers. The study demonstrated the successful preparation of sustained release polymeric nanoparticles of Glibenclamide.

Keywords: Glibenclamide, polymeric nanoparticles, solvent evaporation

INTRODUCTION

Solubility is an important criterion for drug efficacy, independent of route of administration. It also poses a major challenge for pharmaceutical industries, which are developing new pharmaceutical products, since 40% of the active substances being identified are either insoluble or poorly soluble in aqueous media.1 A limiting factor for in vivo performance of poorly water soluble drugs, following oral administration, is their resistance to being wetted and being dissolved into the fluid in the gastrointestinal tract.1 Increasing the dissolution rate of poorly water soluble drugs is thus important for optimizing bioavailability.1 To overcome these problems, various formulation strategies are reported in the literature including the use of surfactants (e.g. tween 80, gelucire), cyclodextrins (e.g. beta-cyclodextrin, hydroxypropyl beta-cyclodextrin), solid dispersions, micronization, lipid based systems.2,3,4,5 However, these approaches are successful in only selected cases.

Nanoparticles are defined as particulate dispersions or solid particles with a size in the range of 10-1000 nm. Nanocapsules are systems in which the drug is confined to a cavity surrounded by a unique polymer membrane, while nanospheres are matrix systems in which the drug is physically and uniformly dispersed. Glibenclamide is one of the most widely used anti hyperglycemic drug. However, glibenclamide’s low bioavailability has been attributed to its poor dissolution properties.1 Hence, in the study it is planned to formulate polymeric nanoparticles of Glibenclamide to improve its dissolution and absorption.

METHODS

Preparation of polymeric nanoparticles of glibenclamide:

Weighed amount of drug was dissolved in dichloromethane, and weighed amount of Eudragit RLPO polymer was dissolved in methanol (Table 1). Drug-polymer solution was prepared by mixing the solutions, followed by vortexing. The drug-polymer solution was homogenized at 10000-13000 rpm and sonicated. The solution was then evaporated using a rotary evaporator, until there were no traces of the organic solvent. The resulting solution was centrifuged and the solution was freeze-dried, after the addition of required quantity of mannitol.

*Corresponding Author
Anup Naha
Department of Pharmaceutics, Manipal College of Pharmaceutical Sciences, Manipal University, Manipal- 576104, Karnataka, India.
E-mail: anupnaha@gmail.com

© 2011-14, JDDT. All Rights Reserved  ISSN: 2250-1177  CODEN (USA): JDDTAO
Table 1: Formulation of various batches of polymeric nanoparticles

<table>
<thead>
<tr>
<th>Ingredient</th>
<th>Drug polymer ratio</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>1:5</td>
</tr>
<tr>
<td>Drug(mg)</td>
<td>5</td>
</tr>
<tr>
<td>Polymer(mg)</td>
<td>25</td>
</tr>
</tbody>
</table>

Optimized batches of the ratios 1:5 and 1:40 were prepared using the same procedure stated above.

Evaluation of polymeric nanoparticles:

Particle size

The particle sizes of the different formulations were measured using Malvern Zeta Sizer (Nano ZS), before and after lyophilization.

Drug content

5mg of the lyophilized sample of each of the optimized formulations was weighed, dissolved in 5ml of the methanol, and the absorbance was measured spectrophotometrically at 300 nm. The percentage entrapment was calculated.

In vitro release

The dissolution study was carried out using Type 2 dissolution with 900ml of phosphate buffer (pH 6.8) for 6 hours, first at intervals of 30 minutes, and then at intervals of an hour. The dissolution medium was kept in a thermostatically controlled water bath, maintained at 37 ±0.5°C. The pre-weighed formulation was filled in a capsule, and then introduced into the dissolution jar. The paddle was rotated at 75rpm. At different time intervals the samples were withdrawn and analyzed spectrophotometrically at 300nm for drug release.

RESULTS AND DISCUSSION

Particle size

The particle sizes of the formulations were measured before and after lyophilization, and the results showed that particles were within the desired size range (Table 2,3).

Table 2: Particle size of formulations

<table>
<thead>
<tr>
<th>Drug polymer ratio</th>
<th>Particle size(nm)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Before lyophilization</td>
</tr>
<tr>
<td>1:5</td>
<td>154</td>
</tr>
<tr>
<td>1:10</td>
<td>95.4</td>
</tr>
<tr>
<td>1:20</td>
<td>100.4</td>
</tr>
<tr>
<td>1:40</td>
<td>133</td>
</tr>
</tbody>
</table>

Table 3: Particle size for Optimized Formulations

<table>
<thead>
<tr>
<th>Drug polymer ratio</th>
<th>Particle size(nm)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Before lyophilization</td>
</tr>
<tr>
<td>1:5</td>
<td>741.6</td>
</tr>
<tr>
<td>1:40</td>
<td>554.5</td>
</tr>
</tbody>
</table>

Drug content

The drug content of the optimized formulations was calculated, after measuring the absorbance at wavelength 300nm. The drug content of the formulation had a percentage entrapment in the range of 50-60%.

In vitro drug release

Drug release profile of 1:4 and 1:5 drug polymer ratios was calculated. Dissolution study was performed for 1:4 and 1:5 drug polymer ratio and percentage cumulative drug release was calculated (%CDD). The drug polymer ratio showed an increase in drug release with time. Formulation exhibited a complete drug release at the end of 6hrs (Figure 1)
CONCLUSION
The drug Glibenclamide was prepared by solvent evaporation method using magnetic stirrer with overnight stirring and the nanoparticles produced were evaluated. The optimized formulation prepared showed similar particle sizes and exhibited an improvement in the drug entrapment efficiency. Formulation exhibited a complete drug release at the end of 6hrs. The present study demonstrated the successful preparation of sustained release polymeric nanoparticles of Glibenclamide.

REFERENCES